Company: KAVL
Filing Date: 2025-08-18
Form Type: 424B5
Source: 0001731122-25-001141
Chunk: 0

Company: Kaival Brands Innovations Group, Inc.
Filing Date: 2025-08-18
Form: 424B5
Chunk 0
---
PROSPECTUS SUPPLEMENT

| (To Prospectus dated August 8, 2025) | Filed Pursuant to Rule 424(b)(5) |

Registration No. 333-288091

<div align='center'>Up to $1,553,536 of Shares of Common Stock</div>

We have entered into an Equity Distribution
Agreement, dated August 15, 2025 (the “Sales Agreement”), with Maxim Group LLC (“Maxim” or the “Sales
Agent”) relating to the sale of shares of our common stock, par value $0.001 per share (the “common stock”),
having an aggregate offering price of up to $1,553,536 from time to time through or to Maxim, acting as sales agent or principal,
pursuant to this prospectus supplement and the accompanying base prospectus. The offering of shares of our common stock
pursuant to the Sales Agreement will terminate upon the earliest of (i) August 15, 2026, (ii) such date, if any, on which we and
Maxim mutually agree to terminate the Sales Agreement or (iii) the sale of all common stock provided for in this prospectus
supplement.

Sales of shares of our common stock, if any, under
this prospectus supplement will be made in sales deemed to be an “at the market offering” as defined in Rule 415(a)(4) promulgated
under the Securities Act of 1933, as amended (the “Securities Act”). Maxim will act as a sales agent and, upon delivery of
a placement notice and subject to the terms and conditions of the Sales Agreement, will use commercially reasonable efforts to sell on
our behalf all of the shares of common stock requested to be sold by us, consistent with its normal trading and sales practices, on mutually
agreed terms between Maxim and us. There is no arrangement for funds to be received in any escrow, trust or similar arrangement.

As sales agent, Maxim will be entitled to compensation at a fixed commission
rate of 3.5% of the gross sales price per share sold under the Sales Agreement. See “Plan of Distribution” for additional
information regarding compensation to be paid to Maxim. In connection with the sale of our common stock on our behalf, Maxim will be deemed
to be an “underwriter” within the meaning of the Securities Act and the compensation of Maxim will be deemed to be underwriting
commissions or discounts. We have